Akorn, Inc., a specialty pharmaceutical company, has filed for Chapter 11 of the U.S. Bankruptcy Code to execute an in‑court sale of its business and address litigation-related overhangs to best position the business for success under new ownership. In connection with the filing, the Company has executed a Restructuring Support Agreement with lenders representing more than 75% of its debt, who will collectively serve as a “stalking horse” bidder in the Company’s sale process an...